Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Aficamten

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cytokinetics Presents Additional Data From SEQUOIA-HCM Study
    Cytokinetics Presents Additional Data From SEQUOIA-HCM Study

    27 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/27/2954593/35409/en/Cytokinetics-Presents-Additional-Data-from-SEQUOIA-HCM-at-the-HCMS-Scientific-Sessions.html

    GLOBENEWSWIRE
    27 Sep 2024
    Share Share
    Research On VASCEPA To Be Presented At EASD Meeting
    Research On VASCEPA To Be Presented At EASD Meeting

    09 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2942721/18362/en/Research-Highlighting-the-Clinical-Impact-of-VASCEPA-VAZKEPA-icosapent-ethyl-in-Patients-with-Diabetes-and-High-Cardiovascular-Risk-and-the-Anti-Lp-a-Oxidation-Mechanistic-Effect-o.html

    GLOBENEWSWIRE
    09 Sep 2024
    Share Share
    Cytokinetics Reports Second Quarter 2024 Financial Results
    Cytokinetics Reports Second Quarter 2024 Financial Results

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2927279/35409/en/Cytokinetics-Reports-Second-Quarter-2024-Financial-Results.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    Cytokinetics Initiates Phase 1 Study Of Aficamten In Healthy Japanese
    Cytokinetics Initiates Phase 1 Study Of Aficamten In Healthy Japanese

    17 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/17/2899567/35409/en/Cytokinetics-Announces-Initiation-of-Phase-1-Study-of-Aficamten-in-Healthy-Japanese-Participants.html

    GLOBENEWSWIRE
    17 Jun 2024
    Share Share
    Cytokinetics secures up to $575M in royalty deal, frustrating investors
    Cytokinetics secures up to $575M in royalty deal, frustrating investors

    24 May 2024

    // BIOPHARMADIVE

    https://www.biopharmadive.com/news/cytokinetics-royalty-aficamten-omecamtiv-mecarbil-funding/716972/

    BIOPHARMADIVE
    24 May 2024
    Share Share
    Cytokinetics, Royalty Pharma Expand Collaboration Up To $575M
    Cytokinetics, Royalty Pharma Expand Collaboration Up To $575M

    22 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/22/2886826/35409/en/Cytokinetics-and-Royalty-Pharma-Announce-Expanded-Strategic-Funding-Collaboration-Totaling-Up-to-575-Million-to-Support-Commercial-Launch-of-Aficamten-and-to-Advance-R-D-Pipeline.html

    GLOBENEWSWIRE
    22 May 2024
    Share Share